PRANDIN
Pronunciation: re-PAG-lin-ide


What it isMeglitinide closing the beta-cell KATP channel; postprandial hyperglycemia in type 2 diabetes.
Why this oneMeal-linked dosing can be omitted with a skipped meal, reducing prolonged hypoglycemia compared with sulfonylureas.
What limits itFrequent meal-time dosing burdens adherence. Gemfibrozil is contraindicated because CYP2C8 inhibition can cause severe hypoglycemia.
Animated chart of estimated U.S. prescriptions per year, Diabetes meds (1923–2026). Repaglinide enters in 1998 (estimated).
Principal riskHypoglycemia; contraindicated with gemfibrozil
Legacy pregnancy categoryMultiple / indication-, trimester- or formulation-dependent
Defining liabilityAgent-specific hypoglycemia, ketoacidosis, volume, renal or gastrointestinal toxicity.
Read the full label on DailyMed ↗
NO BOXED WARNINGS
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Type 2 diabetes | Adults, HbA1c <8% | 0.5 mg before each meal | 0.5-4 mg before meals | 16 mg/day |
| Type 2 diabetes | Adults, HbA1c >=8% | 1-2 mg before each meal | 0.5-4 mg before meals | 16 mg/day |
Titration At least 1 week between dose adjustments
Renal Severe impairment (CrCl 20-40): start 0.5 mg before each meal; CrCl <20/dialysis not studied
Hepatic Use caution; longer intervals between dose adjustments; higher hypoglycemia risk
Dose before each meal (2-4x daily)
Available strengths
Pregnancy Limited data show no clear drug-associated risk; poorly controlled diabetes carries risk
Lactation Not recommended when breastfeeding
Generic entry2013
Open Repaglinide in the interactive console ↗

Open Repaglinide in the interactive console ↗